Regarding capital, I believe people are suggesting that a deal needs to be done which can generation an initial cash payment with further milestone payments as the drug successfully progresses through each agreed milestone trial stage. if we do a deal too soon we may not obtain an optimal deal as the risk is more on the BP with less proof of concept or efficacy etc.
Regarding people’s concerns about first to market with an Alogenic Car-T there is some need for concern as it would be much more beneficial to be first to market with an FDA approved treatment. However being second is not the end of the world either. Imugene can use this technology with their other drugs, which they have stated. Also, market share needs to be developed, it doesn’t come automatically. Commercial success, apart from efficacy is also impacted by the safety profile, manufacturing costs and affordability, manufacturable enough of the drug to meet demand, and finally, being able to convince the medical professionals to use it. There’s still a lot that can impact the success of any drug even after clinical trials.
Not advice DYOR
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)